Arbutus Biopharma (ABUS) Long-Term Investments (2014 - 2024)

Arbutus Biopharma (ABUS) has reported Long-Term Investments for 11 consecutive years, with $3.0 million the latest figure, recorded in Q3 2024.

• Quarterly Long-Term Investments fell 71.76% year-over-year to $3.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3.0 million (down 71.76% YoY) and the FY2023 annual result came in at $6.3 million, down 83.18% from the prior year.
• Long-Term Investments retreated to $3.0 million in Q3 2024 per ABUS's latest filing, from $6.5 million in the prior quarter.
• Over the last five years, Long-Term Investments for ABUS reached as high as $55.4 million in Q3 2022 and fell as low as $1.6 million in Q2 2020.
• A 5-year average of $23.9 million and a median of $31.8 million in 2023 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments plunged 88.87% — and 2021, when it surged 2130.5%.
• Year by year, Long-Term Investments stood at $1.6 million in 2020, then jumped by 2130.5% to $35.7 million in 2021, then advanced by 4.69% to $37.4 million in 2022, then tumbled by 83.18% to $6.3 million in 2023, then plunged by 52.83% to $3.0 million in 2024.
• According to Business Quant data, Long-Term Investments over the past three periods registered $3.0 million, $6.5 million, and $8.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.